{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'assessments will allow robust conclusions to be drawn about', 'the effects of exacerbations on decline in lung function and', 'HRQOL.', 'EXACT PRO will be used to assess breathlessness, cough and', 'presence of sputum, chest symptoms, difficulty bringing up', 'sputum, feeling tired or weak, sleep disturbance, and feeling', 'scared or worried about their condition. Advantages to this', 'approach include standardised data, reduced recall bias, and', 'the potential to identify events and determine resolution based', 'on a predefined scoring algorithm [Leidy, 2011]. Standardised', 'questionnaires completed during study visits include the', 'SGRQ-C and the CAT. The SGRQ-C is designed to assess', 'HRQOL, current health and does not specify a recall period.', 'The CAT is a simple, short, patient-completed instrument', 'to', 'assess HRQOL and symptom burden in patients with COPD.', 'The CAT has good internal consistency and test-retest', 'reliability, correlates strongly with the SGRQ-C, and is able to', 'distinguish between stable patients and those undergoing an', 'AECOPD [Jones, 2012].', 'Number of subjects', 'The target is to enrol approximately 200 eligible moderate to', 'very severe COPD patients.', 'Enppoints', 'Primary (Amended on 19 October 2018)', 'Occurrence of potential bacterial and viral pathogens in', 'sputum of stable COPD patients and during AECOPD,', 'over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological', 'methods, including (but not necessarily limited to) H.', 'influenzae, M. catarrhalis, S. pneumoniae, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii.', '-', 'Viral pathogens, as identified by PCR, including (but', 'not necessarily limited to) RSV, parainfluenza virus,', 'enterovirus/HRV, metapneumovirus, influenza', 'virus, adenovirus, bocavirus and coronavirus.', '19-OCT-2018', '11', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Secondary', 'Occurrence of potential bacterial pathogens in sputum of', 'stable COPD patients and during AECOPD, as measured', 'by real-time qualitative PCR/ quantitative PCR and', 'compared to data from bacteriological methods, over the', 'course of 1 year:', '-', 'Including (but not necessarily limited to)', 'H. influenzae, M. catarrhalis, S. pneumoniae,', 'S. aureus and P. aeruginosa.', 'Occurrence of potential bacterial and viral pathogens', '(overall and by species) in sputum of stable COPD', 'patients by GOLD grade, over the course of 1 year.', 'Occurrence of potential bacterial and viral pathogens', '(overall and by species) in sputum during AECOPD by', 'severity of AECOPD, over the course of 1 year.', 'Incident rate (per subject per year) of AECOPD, overall', 'and by GOLD grade, over the course of 1 year.', 'Severity of AECOPD, overall and by GOLD grade, over', 'the course of 1 year.', 'Duration of AECOPD, overall and by AECOPD severity,', 'over the course of 1 year.', 'CAT score in stable COPD patients and during', 'AECOPD, over the course of 1 year.', 'SGRQ-C score in stable COPD patients, over the course', 'of 1 year.', 'FEV1% of predicted normal value in stable COPD', 'patients, at Pre-Month 0 and Month 12.', 'Healthcare utilisation, over the course of 1 year.', 'Tertiary', 'EXACT-PRO scores in stable COPD patients and during', 'AECOPD, over the course of 1 year.', 'Bacterial load measured by both culture and PCR in', 'COPD and during AECOPD.', 'HRV load measured by PCR in COPD and during', 'AECOPD.', '19-OCT-2018', '12', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}